Search

Author/Creator Birrer, Michael J

1. 2022-RA-1519-ESGO Biomarker testing and first line maintenance treatment patterns in a real-world US cohort of patients with advanced ovarian cancer. (20th October 2022)

Authors:
Veljovich, Dan S; Penson, Richard T; Birrer, Michael J; Long, Gráinne; Wetherill, Graham; Volpe, Stephanie
Journal:
International journal of gynecological cancer
Issue:
Volume 32(2022)Supplement 2
Page Start:
A346
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Issue 10103 (7th October 2017)

Authors:
Tewari, Krishnansu S; Sill, Michael W; Penson, Richard T; Huang, Helen; Ramondetta, Lois M; Landrum, Lisa M; Oaknin, Ana; Reid, Thomas J; Leitao, Mario M; Michael, Helen E; DiSaia, Philip J; Copeland, Larry J; Creasman, William T; Stehman, Frederick B; Brady, Mark F; Burger, Robert A; Thigpen, J ...
Journal:
Lancet
Issue:
Volume 390:Issue 10103(2017)
Page Start:
1654
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Issue 9 (September 2021)

Authors:
Monk, Bradley J; Colombo, Nicoletta; Oza, Amit M; Fujiwara, Keiichi; Birrer, Michael J; Randall, Leslie; Poddubskaya, Elena V; Scambia, Giovanni; Shparyk, Yaroslav V; Lim, Myong Cheol; Bhoola, Snehalkumar M; Sohn, Joohyuk; Yonemori, Kan; Stewart, Ross A; Zhang, Xiaoxi; Perkins Smith, Julia; Linn,...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 9(2021)
Page Start:
1275
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Issue 10 (October 2019)

Authors:
Mirza, Mansoor Raza; Åvall Lundqvist, Elisabeth; Birrer, Michael J; dePont Christensen, Rene; Nyvang, Gitte-Bettina; Malander, Susanne; Anttila, Maarit; Werner, Theresa L; Lund, Bente; Lindahl, Gabriel; Hietanen, Sakari; Peen, Ulla; Dimoula, Maria; Roed, Henrik; Ør Knudsen, Anja; Staff, Synnöve; ...
Journal:
Lancet oncology
Issue:
Volume 20:Issue 10(2019)
Page Start:
1409
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗